Regulation of systemic immune responses utilizing cytokines and antigens
AssigneesWhitehead Institute for Biomedical Research, The Johns Hopkins University School of Medicine
InventorsGlenn Dranoff, Richard C. Mulligan, Drew Pardoll
Life of this patent
Estimating the term…
Abstract
A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.
Claims9
A method of stimulating a systemic immune response of a human to an established tumor, comprising administering to the human a therapeutically effective amount of tumor cells, wherein said tumor cells have been rendered proliferation incompetent by irradiation and have been genetically engineered to express granulocyte-macrophage colony stimulating factor, and wherein said tumor cells elicit a systemic immune response to said established tumor, and wherein said established tumor and said tumor cells are of the same type.
A method of stimulating a systemic immune response of a mammal to an established tumor comprising:
- administering tumor cells, wherein said tumor cells have been rendered proliferation incompetent by irradiation and have been genetically engineered to express granulocyte-macrophage colony stimulating factor, and wherein said tumor cells elicit a systemic immune response to said established tumor, and wherein said established tumor and said tumor cells are of the same type.
A method of suppressing growth of an established tumor in a mammal, comprising administering to said mammal:
- tumor cells wherein said tumor cells have been rendered proliferation incompetent by irradiation and have been genetically engineered to express granulocyte-macrophage colony stimulating factor and wherein said tumor cells elicit a systemic immune response to said established tumor such that growth of said established tumor is suppressed, and wherein said established or an said tumor cell are of the same type.
A method of suppressing growth of melanoma in a human comprising the step of administering to said human a therapeutically effective amount of proliferation-incompetent melanoma cells that have been genetically engineered to express granuloyte-macrophage colony stimulating factor, wherein said melanoma cells elicit a systemic immune response to said melanoma.
A method of suppressing growth of melanoma in a mammal comprising the step of administering to said mammal a therapeutically effective amount of proliferation-incompetent melanoma cells that have been genetically engineered to express granulocyte-macrophage colony stimulating factor, wherein said melanoma cells have been rendered proliferation incompetent by irradiation and wherein said melanoma cells elicit a systemic immune response to said melanoma.
Dependencies are inferred from the claim text.